IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer’s Trial August 19, 2025 Read More »
IGC Pharma Highlights Alzheimer’s Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1 August 12, 2025 Read More »
IGC Pharma Reports IGC-M3’s In Vitro Efficacy Against Alzheimer’s – Targeting key Drivers of Disease Progression August 5, 2025 Read More »
IGC Pharma to Present Advanced AI Platforms for Alzheimer’s Disease at the AAIC 2025 July 23, 2025 Read More »
IGC Pharma’s Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards July 21, 2025 Read More »
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer’s Risk and Accelerate Early Detection July 10, 2025 Read More »
IGC Pharma: Fiscal Year 2025 Financial and Operational Highlights – A Year of Transformative Progress in Alzheimer’s Innovation June 30, 2025 Read More »
IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on June 30, 2025 June 27, 2025 Read More »
IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon June 23, 2025 Read More »
IGC Pharma’s Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer’s Market May 22, 2025 Read More »
